VNRX - Latest News
Volitionrx Ltd (VNRX), operates in Healthcare / Biotechnology, trades on AMEX.
Market capitalization stands near $7.5M. Beta to the broader market is 1.04.
The article list below shows the most recent VNRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VNRX Headlines
VolitionRx Announces Collaboration with Sysmex
prnewswire.com - Jun 17, 2026
HENDERSON, Nev. , June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces
VolitionRx Announces Pricing of $4.6 Million Public Offering
prnewswire.com - Jun 7, 2026
$4. 6 million upfront with up to an additional $2.
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
prnewswire.com - Jun 3, 2026
Seeks Strategic Partners to Deploy Nu. Q® Platform in Outbreak Zones HENDERSON, Nev.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
prnewswire.com - May 27, 2026
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Glob
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 15, 2026
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
How News Affects VNRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VNRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VNRX news questions
- What is the latest VNRX news headline?
- The most recent VNRX headline (Jun 17, 2026) is "VolitionRx Announces Collaboration with Sysmex". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VNRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VNRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VNRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.